What's the outlook for ASX healthcare shares in Q2?

Here are some of the numbers looking ahead.

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX healthcare shares have been underwhelming this year
  • Projections for the industry are a little more optimistic, with some of the larger players looking to secure gains
  • We've crunched the numbers to see what's on the horizon for the industry

ASX healthcare shares have been a mixed bag in 2022. The industry was flourishing during the later part of the last calendar year but took a turn as early as November.

The downside continued along with the broader sell-off in equities. However, unlike most other industries, it has failed to reclaim a good portion of the losses.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is down more than 10% this year to date and is sitting around the same over the past 12 months.

What are the projections?

Healthcare is seen as a 'defensive' industry that is largely insensitive to the business cycle. With this in mind, the current and forward-looking economic climate are of interest to those looking at ASX healthcare shares.

The industry trades on a price-to-earnings (P/E) ratio of 30.09 times at the time of writing, and has delivered a trailing dividend yield of 1.62%.

Some of the largest players, such as CSL Limited (ASX: CSL), Resmed Inc (ASX: RMD), and Sonic Healthcare Limited (ASX: SHL), reside within this portion of the market.

Each of these dominant names has numerous bullish price targets that point to strength in the industry across a diverse array of services.

CSL is rated a buy from 13 out of 16 brokers covering the share, with a $320 consensus price target (all data sourced from Refinitiv Eikon). The CSL share price closed on Friday at $280.43.

Meanwhile, Resmed is also tipped as a buy from nine out of 14 analysts, with a consensus valuation of $36.10. Resmed shares ended Friday's session trading for $34.14 apiece.

Sonic is rated a buy from six out of the 15 analysts covering it, with a $35.86 price target assigned. The Sonic share price is $30.55 as of Friday's close.

Noteworthy is that each consensus price target is priced above the current market value of each share.

In addition, some of the largest ASX healthcare shares are posted in the table below, with their respective fundamentals. All figures are in millions of dollars (except earnings per share and percentage).

NameRevenue [$million]EBITDANet IncomeEPSFree Cash FlowROE (%)
S&P/ASX 200 Health Care Index (ASX: XHJ)1,992.3514.4281.6 $     0.8898.816.3
CSL Limited (ASX: CSL)15,304.95534.73267.2 $     6.97740.219.6
Resmed Inc (ASX: RMD)5,185.01683.51129.5 $     7.68779.125.0
Sonic Healthcare Limited (ASX: SHL)9,340.22835.81460.6 $     3.021356.921.4
Ramsay Health Care Limited (ASX: RHC)13,210.21334.1274.0 $     1.16229.36.9
Cochlear Limited (ASX: COH)1,648.3471.2289.1 $     4.4095.117.1
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)15,58.9557.7349.4 $     0.6072.523.6
Pro Medicus Limited (ASX: PME)94.169.344.4 $     0.4223.948.5
Ansell Limited (ASX: ANN)2,828.7470.9230.0 $     1.79102.610.3
Healius Ltd (ASX: HLS)2,336.2766.9307.9 $     0.52380.915.6
Telix Pharmaceuticals Ltd (ASX: TLS)7.6-71.8-80.5 $   (0.29)-76.7-198.4
Imugene Limited (ASX: IMU)0.0-35.3-37.9 $   (0.01)-35.7-37.2
Nanosonics Ltd (ASX: NAN)120.37.63.7 $     0.012.52.7

With that, we can observe some names from the above list with projected earnings over the next two years in the table below as well.

 EPS   
NamePrevThis yearFY24FY25
S&P/ASX 200 Health Care (GIC) $   1.32 $   0.86 $   1.18 $   1.56
Resmed Inc $   4.32 $   7.68 $   8.47 $   9.46
CSL Ltd $   6.94 $   6.97 $   8.56 $ 10.40
Cochlear Ltd $   4.97 $   4.40 $   5.31 $   6.65
Sonic Healthcare Ltd $   2.73 $   3.02 $   1.72 $   1.56
Ansell Ltd $   2.53 $   1.79 $   2.23 $   2.09
Ramsay Health Care Ltd $   1.80 $   1.13 $   2.98 $   3.13
Fisher & Paykel Healthcare Corporation Ltd $   0.83 $   0.60 $   0.64 $   0.74
Healius Ltd $   0.11 $   0.50 $   0.21 $   0.22
Pro Medicus Ltd $   0.29 $   0.42 $   0.54 $   0.65
Nanosonics Ltd $   0.03 $   0.01 $   0.09 — 
Imugene Ltd $ (0.00) $ (0.01) $ (0.01) $ (0.01)
Telix Pharmaceuticals Ltd $ (0.17) $ (0.29) $ (0.30) $ (0.03)

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »